闻泰科技：坚决反对

Core Viewpoint - The article discusses the recent intervention by the Dutch government regarding Nexperia, a subsidiary of Wentech Technology, which has led to significant operational restrictions and legal actions by foreign executives within the company [1][2][3]. Group 1: Government Intervention - On September 30, 2025, the Dutch Ministry of Economic Affairs issued an order prohibiting Nexperia and its global subsidiaries from making any adjustments to their assets, intellectual property, business, or personnel for one year [2][11]. - Following this, on October 1, 2025, Nexperia's legal representatives filed an urgent request for an investigation and temporary measures with the corporate court, supported by other executives [2][12]. Group 2: Court Rulings - On October 7, 2025, the Dutch corporate court ruled to suspend Zhang Xuezheng from his roles as a non-executive director and executive director at Nexperia, effectively preventing him from fulfilling his CEO duties [3][13]. - The court appointed an independent foreign individual as a non-executive director with decisive voting rights and the authority to represent Nexperia independently [3][13]. Group 3: Operational Impact - Despite the government order and court ruling, Nexperia's daily operations continue, but the company faces temporary changes or delays in decision-making processes [4][14]. - Wentech's control over Nexperia is currently limited, although the economic benefits as a shareholder remain unaffected [4][15]. Group 4: Legal and Strategic Responses - The company is actively communicating with suppliers and customers to maintain stability and is exploring legal remedies while engaging with government departments for support [5][16]. - Wentech emphasizes its commitment to protecting shareholder rights and maintaining operational integrity amidst external pressures [26][27]. Group 5: Financial Performance and Contributions - Nexperia's revenue peaked at €2.36 billion in 2022, with a gross margin increase from 25% in 2020 to 42.4% in 2022 [24]. - The company has significantly increased its R&D investment, from €112 million in 2019 to €284 million in 2024, with a notable rise in patent applications [25][24].